PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma.

Abstract The limited efficacy of conventional therapies for pancreatic ductal adenocarcinoma has led to the growing interest for identifying potential antigenic targets for immunotherapy. Placenta-specific 1 (PLAC1) is a new member of cancer-testis antigens with restricted expression in normal tissues. Ectopic activation of PLAC1 has been found in different types of cancers, but its role in pancreatic ductal adenocarcinoma remains unknown. This study evaluated the protein expression of PLAC1 and its clinical significance in pancreatic ductal adenocarcinoma. We examined PLAC1 expression in 93 pancreatic ductal adenocarcinoma samples by immunohistochemistry. The expression of PLAC1 was detected in 41 (44.1%) patients. Among patients' clinicopathological characteristics, PLAC1 expression was only significantly correlated with tumor differentiation (p = 0.028). Univariate analysis revealed that PLAC1 expression (p = 0.016) and tumor differentiation (p = 0.003) were significantly correlated with poor survival in the whole cohort. Subgroup analysis showed that PLAC1 expression was an independent prognostic biomarker in the perineural invasion positive subgroup (p < 0.05). This study demonstrated that the protein expression of PLAC1 was significantly associated with decreased overall survival in patients with pancreatic ductal adenocarcinoma, indicating that it was a valuable prognostic marker for pancreatic ductal adenocarcinoma and might be a potential target for immunotherapy.
PMID
Related Publications

High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma.

High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC).

The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.

The clinicopathological significance of forkhead box P1 and forkhead box O3a in pancreatic ductal adenocarcinomas.

New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma.

Authors

Mayor MeshTerms
Keywords

Placenta-specific 1

cancer-testis antigen

immunohistochemistry

pancreatic ductal adenocarcinoma

prognosis

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28618924
OWN - NLM
STAT- MEDLINE
DA  - 20170616
DCOM- 20170705
LR  - 20170705
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Expression and clinical significance of placenta-specific 1 in pancreatic ductal 
      adenocarcinoma.
PG  - 1010428317699131
LID - 10.1177/1010428317699131 [doi]
AB  - The limited efficacy of conventional therapies for pancreatic ductal
      adenocarcinoma has led to the growing interest for identifying potential
      antigenic targets for immunotherapy. Placenta-specific 1 (PLAC1) is a new member 
      of cancer-testis antigens with restricted expression in normal tissues. Ectopic
      activation of PLAC1 has been found in different types of cancers, but its role in
      pancreatic ductal adenocarcinoma remains unknown. This study evaluated the
      protein expression of PLAC1 and its clinical significance in pancreatic ductal
      adenocarcinoma. We examined PLAC1 expression in 93 pancreatic ductal
      adenocarcinoma samples by immunohistochemistry. The expression of PLAC1 was
      detected in 41 (44.1%) patients. Among patients' clinicopathological
      characteristics, PLAC1 expression was only significantly correlated with tumor
      differentiation (p = 0.028). Univariate analysis revealed that PLAC1 expression
      (p = 0.016) and tumor differentiation (p = 0.003) were significantly correlated
      with poor survival in the whole cohort. Subgroup analysis showed that PLAC1
      expression was an independent prognostic biomarker in the perineural invasion
      positive subgroup (p &lt; 0.05). This study demonstrated that the protein expression
      of PLAC1 was significantly associated with decreased overall survival in patients
      with pancreatic ductal adenocarcinoma, indicating that it was a valuable
      prognostic marker for pancreatic ductal adenocarcinoma and might be a potential
      target for immunotherapy.
FAU - Yin, Yin
AU  - Yin Y
AD  - 1 Department of Medical Oncology, Fuzhou Dongfang Hospital, Xiamen University,
      Fuzhou, China.
FAU - Zhu, Xu
AU  - Zhu X
AD  - 2 Department of Hepatobiliary Surgery, Fuzhou Dongfang Hospital, Xiamen
      University, Fuzhou, China.
FAU - Huang, Shanshan
AU  - Huang S
AD  - 3 Department of Oncology, The First Affiliated Hospital of Nanchang University,
      Nanchang, China.
FAU - Zheng, Jiawei
AU  - Zheng J
AD  - 4 Department of Medical Oncology, Fuzhou General Hospital of Nanjing Military
      Command, Fuzong Clinical College, Fujian Medical University, Fuzhou, China.
FAU - Zhang, Mengyun
AU  - Zhang M
AD  - 1 Department of Medical Oncology, Fuzhou Dongfang Hospital, Xiamen University,
      Fuzhou, China.
FAU - Kong, Wencui
AU  - Kong W
AD  - 4 Department of Medical Oncology, Fuzhou General Hospital of Nanjing Military
      Command, Fuzong Clinical College, Fujian Medical University, Fuzhou, China.
FAU - Chen, Qun
AU  - Chen Q
AD  - 4 Department of Medical Oncology, Fuzhou General Hospital of Nanjing Military
      Command, Fuzong Clinical College, Fujian Medical University, Fuzhou, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - 1 Department of Medical Oncology, Fuzhou Dongfang Hospital, Xiamen University,
      Fuzhou, China.
FAU - Chen, Xiong
AU  - Chen X
AD  - 1 Department of Medical Oncology, Fuzhou Dongfang Hospital, Xiamen University,
      Fuzhou, China.
AD  - 4 Department of Medical Oncology, Fuzhou General Hospital of Nanjing Military
      Command, Fuzong Clinical College, Fujian Medical University, Fuzhou, China.
FAU - Lin, Kerong
AU  - Lin K
AD  - 5 Department of Gastroenterology, Fuzhou Dongfang Hospital, Xiamen University,
      Fuzhou, China.
FAU - Ouyang, Xuenong
AU  - Ouyang X
AD  - 1 Department of Medical Oncology, Fuzhou Dongfang Hospital, Xiamen University,
      Fuzhou, China.
AD  - 4 Department of Medical Oncology, Fuzhou General Hospital of Nanjing Military
      Command, Fuzong Clinical College, Fujian Medical University, Fuzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (PLAC1 protein, human)
RN  - 0 (Pregnancy Proteins)
SB  - IM
MH  - Adenocarcinoma/*genetics/pathology
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/biosynthesis/*genetics
MH  - Carcinoma, Pancreatic Ductal/*genetics/pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunotherapy
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Placenta/pathology
MH  - Pregnancy
MH  - Pregnancy Proteins/biosynthesis/*genetics
MH  - Prognosis
MH  - Survival Analysis
OTO - NOTNLM
OT  - Placenta-specific 1
OT  - cancer-testis antigen
OT  - immunohistochemistry
OT  - pancreatic ductal adenocarcinoma
OT  - prognosis
EDAT- 2017/06/18 06:00
MHDA- 2017/07/06 06:00
CRDT- 2017/06/17 06:00
AID - 10.1177/1010428317699131 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317699131. doi: 10.1177/1010428317699131.